Treatment with interferon gamma enhances fibrinolysis in systemic sclerosis

Thrombosis Research

Volumn 91, Issue 4, 1998, Pages 203-207

  Gluszko, Piotr ^a   Undas, Anetta ^a   Kwasny, Beata ^a   Musialł, Jacek ^a   Szczeklik, Andrzej ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Fibrinolysis; Interferon gamma; Systemic sclerosis

Indexed keywords

ALPHA 2 ANTIPLASMIN; PLASMIN; RECOMBINANT GAMMA INTERFERON;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG INDUCED DISEASE; FEMALE; FEVER; FIBRINOLYSIS; HEADACHE; HUMAN; IMMUNOTHERAPY; MALE; MYALGIA; PRIORITY JOURNAL; SCLEROSIS; SUBCUTANEOUS DRUG ADMINISTRATION; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME;

ADULT; FEMALE; FIBRINOLYSIS; HUMANS; INTERFERON-GAMMA, RECOMBINANT; MALE; MIDDLE AGED; SCLERODERMA, SYSTEMIC;

EID: 0032529125     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(98)00084-X     Document Type: Article

References (20)

1. Kahaleh M.B. The vascular endothelium in scleroderma. Int Rev Immunol. 12:1995;227-245.
2. Matucci-Cerinic M., Lotti T., Lombardi A. Cutaneous and plasma fibrinolytic activity in systemic sclerosis. Evidence of normal plasminogen activation. Int J Dermatol. 29:1990;644-648.
3. Lotti T., Campanile G., Matucci-Cerini M. Cutaneous and plasma fibrinolytic activities are not deficient in patients with systemic sclerosis. J Am Acad Dermatol. 30:1993;813-814.
4. Wilson D., Edworthy S.M., Hart D.A., Fritzier M.J. The safety and efficacy of low-dose tissue plasminogen activator in the treatment of systemic sclerosis. J Dermatol. 22:1995;637-642.
5. Kahan A., Amor B., Menkes C.J., Stauch G. Recombinant interferon gamma in the treatment of systemic sclerosis. Am J Med. 87:1989;273-277.
6. Polisson R.P., Gilkeson G.S., Pyun E.N., Pisetsky D.S., Smith E.A., Simon L.S., Simon L.S. A multicenter trial of recombinant human interferon gamma in patients with systemic sclerosis. effects on cutaneous fibrosis and interleukin-2 receptor levels J Rheumatol. 23:1996;654-658.
7. Mulder A.B., Zwaveling J.H., Smid M., Maring J.K., van Ginkel R.J., Girbes A.R.J., Schraffordt Koops H. Augmented procoagulant activity in cancer patients treated with recombinant interferon gamma in addition to recombinant tumor necrosis factor and melphalan. Thromb Haemost. 76:1996;897-901.
8. Gluszko P., Undas A., Styliani A., Szczeklik A., Schmaier A.H. Administration of gamma interferon in human subjects decreases plasminogen activation and fibrinolysis without influencing C1 inhibitor. J Lab Clin Med. 123:1993;232-240.
9. Musial J., Undas A., Duplaga M., Milewski M., Radwan J., Szczeklik A. Effects of interferon-gamma on fibrinolysis and thrombin generation in patients with atopic dermatitis. Thromb Haemost. Suppl 1):1995;73.
10. Bryckaert M., Fontenay M., Liote F., Bellucci S., Carriou R., Tobolem G. Increased mitogenic activity of scleroderma serum. inhibitory effect of human recombinant interferon-gamma AnnRheum Dis. 53:1994;776-779.
11. Musial J., Milewski M., Undas A., Kopinski P., Duplaga M., Szczeklik A. Interferon gamma in the treatment of atopic dermatitis. Influence on T-cell activation Allergy. 50:1995;520-523.
12. Reid T.J., Lombardo F.A., Redmond J., Hammond S.L., Coffey J.A., Ozer H. Digital vasculitis associated with interferon therapy. Am J Med. 92:1992;702-703.
13. Creutzig A., Freund M. Severe Raynaud's syndrome associated with interferon therapy. Angiology. 47:1996;185-187.
14. Corssmit E.P.M., Levi M., Hack C.E., Cate J.W., Sauwerwein H.P., Romijn J.A. Fibrinolytic response to interferon alpha in healthy human subjects. Thromb Haemost. 75:1996;113-117.
15. Hayashi T., Ro S., Kamogawa A., Kobayashi Y., Suzuki Y., Imai M., Okuse C., Ozaki M., Iwabuchi S., Murayama M. Changes in plasma tissue plasminogen activator and plasminogen activator inhibitor 1 by the interferon treatment for chronic hepatitis. Rhinsho Byori. 43:1995;948-952.
16. Kahaleh B., Matucci-Cerinic M. Raynaud's phenomenon and scleroderma. Arthritis Rheum. 38:1995;1-4.
17. Fritzler M.J., Hart D.A., Wilson D., Garcia-De La Torre I., Salazar-Param O.M., Vazquez-Del Mercado M., Senecal J.L., Loyau S., Angles-Cano E. Antibodies to fibrin bound tissue type plasminogen activator in systemic sclerosis. J Rheumatol. 22:1995;1688-1693.
18. Lewandowski K., Turowiecka Z., Puszczewicz J., Mackiewicz S., Zawilska K. Antiphospholipid antibodies and disturbances of phospholipid dependent coagulation tests in patients with systemic sclerosis and severe peripheral ischaemia. Thromb Res. 81:1996;693-695.
19. Peng S.L., Fatenejad S., Craft J. Scleroderma. a disease related to damaged proteins Nature Med. 3:1997;276-278.
20. Kahaleh M.B., Osborn I., Leroy E.C. Increased factor VII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud's phenomenon. Ann Intern Med. 94:1981;482-484.